Published in Cancer Med on June 04, 2012
A novel non-canonical Wnt signature for prostate cancer aggressiveness. Oncotarget (2016) 0.75
Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics. Target Oncol (2017) 0.75
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol (2006) 7.36
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol (2009) 2.94
Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res (2006) 2.86
Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol (1993) 2.69
Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell (2003) 2.49
Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol (2004) 2.35
The opposing roles of Wnt-5a in cancer. Br J Cancer (2009) 2.07
Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol (1997) 1.98
Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res (2002) 1.93
Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res (2005) 1.77
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer (2009) 1.77
WNT5A--target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis (2007) 1.76
Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene (2010) 1.68
Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer. J Clin Oncol (2005) 1.67
WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res (2008) 1.50
Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res (2005) 1.41
A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J Biol Chem (2005) 1.32
The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res (2008) 1.28
Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene (2005) 1.27
A novel role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One (2010) 1.26
Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int (2008) 1.25
Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma. Dig Liver Dis (2008) 1.20
Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol (2011) 1.01
Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One (2011) 0.99
Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS (2008) 0.99
Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Mod Pathol (2011) 0.97
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ (2014) 4.75
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol (2016) 2.94
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2013) 2.74
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2010) 2.39
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
Gamma knife surgery for dural arteriovenous shunts: 25 years of experience. J Neurosurg (2006) 2.14
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol (2012) 1.96
Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res (2002) 1.93
Natural history of dural arteriovenous shunts. Stroke (2008) 1.91
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol (2010) 1.86
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res (2011) 1.82
The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications. Eur Urol (2011) 1.81
Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res (2005) 1.77
Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol (2010) 1.75
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors. Carcinogenesis (2002) 1.68
Image noise reduction algorithm for digital subtraction angiography: clinical results. Radiology (2013) 1.64
Hemodynamic perturbations during robot-assisted laparoscopic radical prostatectomy in 45° Trendelenburg position. Anesth Analg (2011) 1.63
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J Leukoc Biol (2010) 1.62
Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int (2007) 1.61
Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr (2012) 1.61
Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. Eur Urol (2012) 1.60
Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol (2012) 1.60
Posterior musculofascial reconstruction after radical prostatectomy: a systematic review of the literature. Eur Urol (2012) 1.57
A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur Urol (2012) 1.56
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate (2002) 1.54
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl (2005) 1.54
Training, credentialing, proctoring and medicolegal risks of robotic urological surgery: recommendations of the society of urologic robotic surgeons. J Urol (2009) 1.53
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol (2008) 1.49
Tissue shrinkage after fixation with formalin injection of prostatectomy specimens. Virchows Arch (2006) 1.48
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer (2008) 1.48
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
Prognostic significance of patterns of seminal vesicle invasion in prostate cancer. Histopathology (2013) 1.46
Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res (2006) 1.46
Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells. Mol Cell Biol (2006) 1.45
Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. Nucleic Acids Res (2006) 1.43
p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med (2004) 1.42
Retrospective multicenter study of Solitaire FR for revascularization in the treatment of acute ischemic stroke. Stroke (2012) 1.41
Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res (2005) 1.41
Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr (2007) 1.40
Quantitative assessment of the subepithelial collagen band does not increase the accuracy of diagnosis of collagenous colitis. Am J Clin Pathol (2008) 1.39
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A (2009) 1.35
Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol (2008) 1.35
Robotic equipment malfunction during robotic prostatectomy: a multi-institutional study. J Endourol (2008) 1.32
miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer (2010) 1.32
A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J Biol Chem (2005) 1.32
Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate (2004) 1.31
The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol (2010) 1.30
Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate (2002) 1.30
The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res (2008) 1.28
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol (2011) 1.27
Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev (2007) 1.27
Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS(®)) society recommendations. Clin Nutr (2013) 1.26
The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch (2006) 1.25
A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. Proc Natl Acad Sci U S A (2009) 1.25
Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer (2013) 1.25
Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int (2011) 1.23
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol (2010) 1.22
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol (2010) 1.22
Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol (2010) 1.19
Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate (2005) 1.18
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J Natl Cancer Inst (2008) 1.18
Wnt-5a-CKI{alpha} signaling promotes {beta}-catenin/E-cadherin complex formation and intercellular adhesion in human breast epithelial cells. J Biol Chem (2009) 1.18
A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer (2008) 1.17
Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol (2013) 1.17
Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Hum Reprod (2002) 1.16
Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol (2013) 1.15
Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One (2012) 1.15
Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res (2010) 1.15
Management of patients with brain arteriovenous malformations. Eur J Radiol (2003) 1.15
Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One (2012) 1.14